The overall objective of this research proposal is the identification of genetic marker relevant for the pathogenesis, diagnosis and clinical monitoring of lymphoid malignancies, including acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) and multiple myeloma (MM). The general experimental plan involves: 1) test the utility of known oncogene alterations as clinico-pathologic markers; 2) identify novel oncogene alterations which are consistently associated with lymphoid malignancies; and 3) develop sensitive and specific assays to monitor disease spread and remission. In particular, the following specific aims will be pursued: 1) Test the utility of oncogene alterations as clinico-pathologic markers. We have already determined that ras oncogene mutations are frequently associated with ALL and MM. We will test the clinico-prognostic relevance of ras oncogene mutations in these two malignancies by screening for ras mutations large panels of ALL and MM cases and correlating the results with a number of relevant clinical parameters. 2) Identification of novel oncogene alterations. Preliminary data indicate that a significant fraction of NHL cases contains DNA sequences which are able to cause the tumorigenic conversion of NIH3T3 cells. These sequences do not correspond to any of the known ras oncogenes. Transforming sequences have been cloned from one case and do not appear to correspond to any known oncogene. We plan to characterize these sequences, identify the putative proto-oncogenes, identify the nature of the activating mutations and determine their frequency in lymphoid malignancies. Eventually, we will test the utility of these alterations as clinico-pathologic markers as in 1). 3) Development and clinico-prognostic testing of assays to monitor disease spread and remission. We have recently developed a polymerase chain reaction (PCR)-based assay which allows the detection of clonal lymphoid cells in virtually all types of B-cell malignancies at a sensitivity of 1/10-5 cells, independent of previous cytogenetic analysis and presence of known chromosomal translocations. We will use this assay to determine: i) the extent of disease spread, i.e. bone marrow, peripheral blood and/or lymphnodes, depending upon the type of malignancy; and ii) the presence of minimal residual disease during remission. The data collected from representative panels of cases will be correlated with relevant clinico- prognostic parameters.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA044029-08
Application #
2091350
Study Section
Pathology A Study Section (PTHA)
Project Start
1989-07-15
Project End
1994-11-30
Budget Start
1993-12-01
Budget End
1994-11-30
Support Year
8
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Columbia University (N.Y.)
Department
Pathology
Type
Schools of Medicine
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10027
Hauptschein, R S; Gaidano, G; Rao, P H et al. (2000) An apparent interlocus gene conversion-like event at a putative tumor suppressor gene locus on human chromosome 6q27 in a Burkitt's lymphoma cell line. DNA Res 7:261-72
Butler, M P; Wang, S I; Chaganti, R S et al. (1999) Analysis of PTEN mutations and deletions in B-cell non-Hodgkin's lymphomas. Genes Chromosomes Cancer 24:322-7
Pasqualucci, L; Migliazza, A; Fracchiolla, N et al. (1998) BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. Proc Natl Acad Sci U S A 95:11816-21
Hauptschein, R S; Gamberi, B; Rao, P H et al. (1998) Cloning and mapping of human chromosome 6q26-q27 deleted in B-cell non-Hodgkin lymphoma and multiple tumor types. Genomics 50:170-86
Chaganti, S R; Rao, P H; Chen, W et al. (1998) Deregulation of BCL6 in non-Hodgkin lymphoma by insertion of IGH sequences in complex translocations involving band 3q27. Genes Chromosomes Cancer 23:328-36
Chen, W; Butler, M; Rao, P H et al. (1998) The t(2;3)(q21;q27) translocation in non-Hodgkin's lymphoma displays BCL6 mutations in the 5' regulatory region and chromosomal breakpoints distant from the gene. Oncogene 17:1717-22
Chen, W; Iida, S; Louie, D C et al. (1998) Heterologous promoters fused to BCL6 by chromosomal translocations affecting band 3q27 cause its deregulated expression during B-cell differentiation. Blood 91:603-7
Chaganti, S R; Chen, W; Parsa, N et al. (1998) Involvement of BCL6 in chromosomal aberrations affecting band 3q27 in B-cell non-Hodgkin lymphoma. Genes Chromosomes Cancer 23:323-7
Carbone, A; Gaidano, G; Gloghini, A et al. (1997) BCL-6 protein expression in AIDS-related non-Hodgkin's lymphomas: inverse relationship with Epstein-Barr virus-encoded latent membrane protein-1 expression. Am J Pathol 150:155-65
Carbone, A; Gloghini, A; Gaidano, G et al. (1997) BCL-6 protein expression in human peripheral T-cell neoplasms is restricted to CD30+ anaplastic large-cell lymphomas. Blood 90:2445-50

Showing the most recent 10 out of 55 publications